Fulcrum Therapeutics, Inc.
FULC · XNASCIK 1680581fmd_1RP844J995P0TRZ5HA7QXB1QWNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 9 | 19 | 6 | 3 | 80 | 0 |
| Research and development | 25 | 71 | 59 | 70 | 77 | 72 | 63 | 56 |
| Total operating expenses | 33 | 84 | 80 | 100 | 119 | 113 | 102 | 85 |
| Operating income | (33) | (84) | (72) | (81) | (113) | (111) | (22) | (85) |
| Income tax expense | – | – | – | – | – | – | 0 | 0 |
| Net income | (33) | (83) | (71) | (81) | (110) | (97) | (10) | (75) |
| Net income to common shareholders | (39) | (90) | (71) | – | – | – | – | – |